Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOENIX-CCA4 futibatinib dose study in FGFR2-rearranged advanced cholangiocarcinoma
jRCT2051230018Phase 2Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of futibatinib in cholangiocarcinoma (CCA) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall response rate. Started Jun 2023; status: active, not recruiting.
02
Drugs
futibatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2051230018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230018.